COZADD BRUCE C 4
4 · Jazz Pharmaceuticals plc · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
Jazz Pharmaceuticals (JAZZ) Director Bruce C. Cozadd Sells Shares
What Happened
Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc, sold a total of 6,000 ordinary shares in open-market transactions on April 1, 2026. The sales were reported in three blocks: 3,684 shares at $190.22 for $700,778; 2,292 shares at $190.94 for $437,631; and 24 shares at $191.74 for $4,602. Total reported proceeds from these disposals were $1,143,011. These were sales (not purchases) and therefore represent liquidity by the insider rather than an additional investment.
Key Details
- Transaction date: April 1, 2026 (filed April 3, 2026 — appears timely under the two-business-day rule).
- Trade details: 3,684 sh @ $190.22 ($700,778); 2,292 sh @ $190.94 ($437,631); 24 sh @ $191.74 ($4,602).
- Total shares sold: 6,000; total proceeds: $1,143,011.
- Shares owned after transaction: Not disclosed in the provided filing excerpt.
- Notable footnotes:
- The sales were made pursuant to a Rule 10b5‑1 plan adopted Nov 26, 2025; transactions occurred automatically and were nondiscretionary.
- Some reported prices reflect weighted-average prices across multiple executions; the reporting person offers to provide full transaction-level details on request.
- Filing timeliness: Filing date (Apr 3, 2026) appears timely for an Apr 1, 2026 transaction.
Context
Sales executed under a pre-arranged 10b5‑1 plan are common for insiders managing routine equity liquidity and are carried out automatically regardless of short-term company developments. This filing documents the disposition and associated proceeds but does not by itself indicate the insider’s view of the company’s long-term prospects.
Insider Transaction Report
- Sale
Ordinary Shares
[F1][F2]2026-04-01$190.22/sh−3,684$700,778→ 386,998 total - Sale
Ordinary Shares
[F1][F3]2026-04-01$190.94/sh−2,292$437,631→ 384,706 total - Sale
Ordinary Shares
[F1]2026-04-01$191.74/sh−24$4,602→ 384,682 total
Footnotes (3)
- [F1]This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
- [F2]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $189.60 to $190.5603. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- [F3]Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $190.6051 to $190.5982. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.